Highlights Johnson & Johnson

Stocks

JNJ

US4781601046

Pharmaceuticals

Market Closed - NYSE Other stock markets 23:00:02 16/07/2026 +03			5-day change	1st Jan Change
249.97 ^USD	+1.19%		-3.52%	+20.79%

07-16	Argus Lifts Johnson & Johnson Price Target to $290 From $275	MT
07-16	Johnson & Johnson's Innovative Medicine Segment Momentum Continues to Build into 2027, RBC Says	MT

Highlights

07-16	J&J's DePuy Synthes Acquires Expanding Innovations	DJ
07-16	Abbott raises 2026 profit forecast on heart device strength	RE
07-15	Healthcare Stocks Stable Amid Broad Markets Rise -- Healthcare Roundup	DJ
07-15	Johnson & Johnson Lifts Full-Year Outlook Following Second-Quarter Beat	MT
07-15	Johnson & Johnson Reports Earnings Results for the Second Quarter and Six Months Ended June 28, 2026	CI
07-15	Johnson & Johnson Provides Earnings Guidance for the Full Year 2026	CI
07-15	Johnson & Johnson Declares A Cash Dividend for the Third Quarter of 2026 on Common Stock, Payable on September 8, 2026	CI
07-15	Johnson & Johnson Keeps Quarterly Dividend to $1.34 a Share, Payable Sept. 8 to Stockholders of Record Aug. 25	MT
07-15	Johnson & Johnson Fiscal Q2 Adjusted Earnings, Sales Increase; Fiscal 2026 Guidance Lifted	MT
07-15	J&J posts mixed results, shares seen lower
07-15	J&J Bumps Up Guidance as 2Q Sales Rise	DJ
07-15	(JNJ) Johnson & Johnson Expects 2026 Reported Sales Range $100.8B - $101.4B, vs. FactSet Est of $101.06B	MT
07-15	(JNJ) Johnson & Johnson Expects 2026 Adjusted EPS Range $11.60 - $11.75, vs. FactSet Est of $11.63	MT
07-15	Earnings Flash (JNJ) Johnson & Johnson Reports Q2 Revenue $25.31B, vs. FactSet Est of $25.02B	MT
07-15	J&J medtech miss overshadows earnings beat	RE
07-15	Earnings Flash (JNJ) Johnson & Johnson Posts Q2 Adjusted EPS $2.90 per Share, vs. FactSet Est of $2.85	MT
07-09	Goldman Sachs is betting heavily on Johnson & Johnson's Icotyde
07-08	Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says	MT
07-08	Johnson & Johnson Receives Fda Approval for Dual Energy Thermocool Smarttouch Sf Platform	CI
07-01	UK Approves J&J's Gemcitabine Delivery System for Bladder Cancer Patients	MT
06-26	Johnson & Johnson Presents New IMAAVY Data at European Academy of Neurology 2026 Congress Reinforcing Sustained Disease Control in Generalized Myasthenia Gravis	CI
06-26	European Medicines Agency Panel Recommends Label Expansion for Janssen-Cilag's Multiple Myeloma Drug	MT
06-26	EU Regulatory Panel Recommends Expanding Janssen Cilag's Psoriasis Drug Indications	MT
06-26	European Medicines Agency Panel Recommends Change to Marketing Authorization Terms for J&J Unit's HIV-1 Treatment	MT
06-22	Definium's LSD-based depression pill delivers strong late-stage results, shares surge	RE